Clinical Trial Detail

NCT ID NCT02332980
Title A Phase II Study of Anti-PD-1 Antibody (MK-3475) in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Other Low Grade B Cell Non-Hodgkin Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Mayo Clinic
Indications

chronic lymphocytic leukemia

Therapies

Pembrolizumab

Age Groups: adult

No variant requirements are available.